Abstract
The glycine transporter type 1 (GlyT1) has emerged as a key novel target for the treatment of schizophrenia. We have recently discovered and developed [11C]RO5013853 as a novel positron emission tomography tracer for GlyT1 for which a reliable five-step synthetic route was established. The incorporation of the radioisotope was achieved in the final step through methylation of a sodium sulfinate precursor, itself easily accessible upon reduction of the corresponding sulfonyl-chloride analog. [11C] RO5013853 was prepared with high specific activity (>49 GBq/μmol) and high radiochemical purity (100%). A validation study of [11C]RO5013853 in animal imaging studies is in progress.
Original language | English (US) |
---|---|
Pages (from-to) | 702-707 |
Number of pages | 6 |
Journal | Journal of Labelled Compounds and Radiopharmaceuticals |
Volume | 54 |
Issue number | 11 |
DOIs | |
State | Published - Sep 2011 |
Keywords
- GlyT1
- PET
- carbon-11
- glycine
- radiolabeling
- transporter
ASJC Scopus subject areas
- Drug Discovery
- Analytical Chemistry
- Biochemistry
- Radiology Nuclear Medicine and imaging
- Spectroscopy
- Organic Chemistry